Drug Profile
CARG 201
Alternative Names: CARG-201; Hepatitis B vaccine - CaroGen CorporationLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator CaroGen
- Developer CaroGen; Yale University School of Medicine
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Hepatitis-B in USA
- 23 Jul 2021 CARG 201 is still in preclinical development for Hepatitis B in USA (CaroGen pipeline, July 2021)
- 28 Oct 2019 No recent reports of development identified for preclinical development in Hepatitis-B in USA